CYTK News and Press, Cytokinetics Incorporated From 03/16/24

2024-03-16 03:43:48 ET Summary Cytokinetics' share price is down 40% from January highs due to Novartis reportedly giving up on acquiring the company, and more recently, due to CEO Blum talking down buyout prospects. Blum said the company had not initiated a sale process and empha...

2024-03-13 14:25:31 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the technology sector has been enjoying ridiculous returns, it’s inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks . T...

2024-03-11 15:54:09 ET More on Cytokinetics Cytokinetics, Incorporated (CYTK) Q4 2023 Earnings Call Transcript Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade) Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upg...

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March: Leerink Global Biopharma Conference: Robert I. Blum, President and C...

Super Micro Computer and Deckers Outdoor Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 Super Micro Computer and Deckers Outdoor Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 PR News...

SOUTH SAN FRANCISCO, Calif., and ALBANY, Ga., and WASHINGTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), together with The Mended Hearts, Inc. and WomenHeart: The National Coalition for Women with Heart Disease, today announced the launch of ENACT: Empower, Navig...

Topline Results from SEQUOIA-HCM Announced in December Showed Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint and Improvements in All Secondary Endpoints Company Plans to Submit New Drug Application for Aficamten to FDA in Q3 2024 ...

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...

2024-02-16 10:29:22 ET More on Novartis Novartis And MorphoSys Are A Perfect Match Novartis AG (NVS) Q4 2023 Earnings Call Transcript Novartis AG 2023 Q4 - Results - Earnings Call Presentation MorphoSys ADRs gain after definitive merger agreement with Novarti...

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host...